Presented by presented by Beaker.com
First shots fired between Novartis, Amgen in biosimilars battle
Jeffrey Clark - Posted: 7/30/2014
The FDA has agreed to review Sandozs biologics license application for Zarzio, its biosimilar version of Amgens Neupogen.  Neupogen is one of the products that set the foundation and helped build Amgen into what it is today.  The treatment is indicat[...]
Johnson and Johnson CEO Gorsky not surprised by Medtronic, Covidien merger
Jeffrey Clark - Posted: 7/29/2014
Johnson & Johnson CEO Alex Gorsky was recently asked about his reaction to Medtronics merger with Covidien.  Calmly, he replied that J&J saw something like this coming a mile away and beat its competitors to the punch. If you think back to about thre[...]
Righting a wrong: FDA approves painkiller to counter abuse
Jeffrey Clark - Posted: 7/28/2014
The FDA wants to help drug companies avoid the abuse of their pharmaceuticals. The agency approved a new version of Oxycodone, specifically designed to abuse. The new formulation from Purdue Pharmaceuticals contains naloxone, an ingredient that negat[...]
Google partners with Novartis for smart contact lenses, to enter diabetes market
Jeffrey Clark - Posted: 7/24/2014
Novartis has announced a partnership to develop next generation contact lenses with Google, capable of constant blood glucose monitoring and enhanced vision capabilities. The agreement is among recent moves into the health care sector by technology g[...]
Other life sciences regions playing catch up to Boston
Jeffrey Clark - Posted: 7/24/2014
Massachusetts is the capital of the life sciences industry in the US. For decades, the debate has been raging, fueled by muddled rankings, biased reporting and mostly economic development dollars.  But over the past three years or so, Boston has emer[...]
Abbott CEO defends tax inversion strategy amongst life sciences firms
Jeffrey Clark - Posted: 7/22/2014
In the wake of Pfizer/AstraZeneca and AbbVie/Shire, Abbott Labs CEO Miles White sets the record straight on tax inversions in an op-ed article for the Wall Street Journal. Inversions are legal. Not abuse. Not cheating. To those spouting the histrioni[...]
Allergan sheds workforce to fend off Valeant
Jeffrey Clark - Posted: 7/21/2014
Allergan delivered its much anticipated second quarter update this morning. Questions were looming, what would the company do to fend off Valeants hostile takeover? According to the call, Allergan will cut 1,500 jobs and eliminate another 250 vacant [...]
AbbVie acquires Shire for $54B, joins tax inversion trend
Jeffrey Clark - Posted: 7/21/2014
AbbVie agreed on Friday to buy Shire for around $54 billion, in the biggest takeover deal so far this year. The combination would create one of the 50 largest companies in the world, with nearly $25 billion in annual sales and about 30,000 employees.[...]
Roche dominates in cancer treatments
Jeffrey Clark - Posted: 7/20/2014
Remember how persistant Roche was in its pursuit of Genentech back in 2009?  When Roche paid $46.8 billion in 2009 to gain full control of Genentech, the fear was the stodgy old Swiss company would stifle the innovative approach to drug development a[...]
Over 100 life sciences professionals on doomed MH17 flight
Jeffrey Clark - Posted: 7/18/2014
The life sciences industry has been rocked by the recent news that more than 100 of the worlds leading HIV researchers were onboard the Malaysian Airlines flight that crashed yesterday. At this point, there are more questions than answers regarding t[...]
CEO discusses ground-breaking FDA approval of ReWalk
Jeffrey Clark - Posted: 7/18/2014
ReWalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with Spinal Cord Injury (SCI) to stand upright and walk. ReWalk, the only exoskeleton with FDA clearance via clinical studies and extensive perfo[...]
Mylan CEO talks Abbott deal, tax inversion
Jeffrey Clark - Posted: 7/17/2014
Mylan CEO talks Abbott deal, tax inversion
Immunotherapy is a gold mine for growth, Big Pharma chasing
Jeffrey Clark - Posted: 7/16/2014
A Decision Resources report forecasts that the global market for cancer immunotherapy will reach almost $9 billion in 2022, compared with $1.1 billion two years ago. According to the report, the market will initially be dominated by a handful of comp[...]
FDA approves MannKind inhaled insulin for diabetes
Jeffrey Clark - Posted: 7/15/2014
MannKind has obtained the FDAs approval to market its fast-acting, inhaled insulin Afrezza as a treatment for type 1 and type 2 diabetes. The drug comes in powder form and is delivered using a cartridge.  Due to its potential risks in patients with a[...]
Actavis CEO discusses completion of Forest Labs deal, corporate tax reform
Jeffrey Clark - Posted: 7/14/2014
Actavis CEO Brent Saunders explains why the deal with Forest Labs makes his company a global, balanced company in both generic and specialty pharmaceuticals. In his words, we want to keep our generic DNA. In this CNBC interview, the discussion with S[...]
Sanofi CEO on CNBC
Jeffrey Clark - Posted: 7/10/2014
The key to improved healthcare and the success of the life sciences industry is a focus on chronic diseases, says Sanofi CEO Chris Viehbacher. In this CNBC video, Viehbacher discusses how the pharmaceutical industry is preparing for the onslaught of [...]
Salix joins the inversion crowd with Irish merger
Jeffrey Clark - Posted: 7/9/2014
Add North Carolina-based Salix Pharmaceuticals to the list of companies relocated their corporate headquarters overseas in a newly popular inversion strategy.  Salix joins Medtronic/Covidien, Valeant, and potential future deals between Pfizer/AstraZe[...]
AbbVie raises offer for Shire in another inversion deal
Jeffrey Clark - Posted: 7/9/2014
AbbVie has raised its bid to acquire Shire, which rejected its prior takeover offer worth $46 billion. The new offer is up 11% and is worth roughly $52B. AbbVie is the latest American company to attempt a so-called inversion, in which it would acquir[...]
Cubist leads antibiotics when no one else will
Jeffrey Clark - Posted: 7/8/2014
Michael Bonney, Cubist Pharmaceuticals CEO, shares his perspective as the worlds largest antibiotic R&D and commercialization company. The companys most recent success is the FDAs approval of Sivextro, a new antibiotic designed to treat skin infe[...]
Sir Richard Branson wraps up BIO convention in San Diego
Jeffrey Clark - Posted: 7/7/2014
Sir Richard Branson made an appearance at the BIO 2014 International Convention in San Diego last month.  Both Branson and Hillary Clinton were well compensated for their time at the convention.  One was a pre-campaign stop for the 2016 presidential [...]
Advamed: The MedTech Minute
Jeffrey Clark - Posted: 7/3/2014
Advamed: The MedTech Minute
Johnson and Johnson abandons potential Botox rival
Jeffrey Clark - Posted: 7/2/2014
Johnson & Johnson announced it will halt development of PurTox, its anti-wrinkle treatment designed to compete with Allergans Botox.   J&J acquired the product when it purchased breast-implant-maker Mentor for $1.1B in 2009.   For years, Mentor was c[...]
Cool technology: Luke Skywalker prosthetic arm gains FDA approval
Jeffrey Clark - Posted: 7/1/2014
The DEKA Arm is an electronic prosthetic that mimics natural arm and hand movement with an amazing level of finesse. Its controlled by electrical signals generated by the patients muscles. The prostheses was developed by Dean Kamen, the inventor of t[...]
Advamed launches The MedTech Minute video series
Jeffrey Clark - Posted: 6/30/2014
In the first installment in a new video series on the value of life-changing medical technology, Michael Rousseau, Chief Operating Officer of St. Jude Medical, explains how innovation is providing exceptional patient benefits while helping to keep he[...]
Allergan losing momentum in its attempt to fend off Valeant
Jeffrey Clark - Posted: 6/27/2014
Allergan has struck an agreement for a special meeting of Allergan shareholders, in the face of a $53 billion takeover effort by Pershing Square and Valeant Pharmaceuticals. Two weeks ago, Pershing Square, the hedge fund run by Bill Ackman, sued Alle[...]
 
Beaker.com
Johnson and Johnson CEO G[...]
Johnson & Johnson CEO Alex Gorsky was recently asked about his reaction to Medtronic’s merger with C[...]
AbbVie acquires Shire for[...]
AbbVie agreed on Friday to buy Shire for around $54 billion, in the biggest takeover deal so far thi[...]
Over 100 life sciences pr[...]
The life sciences industry has been rocked by the recent news that more than 100 of the world’s lead[...]
CEO discusses ground-brea[...]
ReWalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individ[...]
Mylan CEO talks about Abb[...]
Mylan CEO talks about Abbott deal and tax inversion.